-

Rapid Medical™ Appoints Industry Veteran Nir Nimrodi to Its Board of Directors

SOUTHLAKE, Texas & YOKNEAM, Israel--(BUSINESS WIRE)--Rapid Medical™, a leading developer of active endovascular devices, today announced the appointment of Nir Nimrodi to its Board of Directors. Nimrodi brings more than three decades of global leadership in the biotechnology and life sciences industries, with extensive experience in strategic growth, commercialization, and M&A for high-impact healthcare companies.

With a career spanning executive roles at companies including Accellix, Intrexon, Life Technologies, and Proneuron Biotechnologies, Nimrodi has consistently driven innovation and scale across diverse healthcare sectors.

Share

“I am honored to join Rapid Medical’s Board and contribute to the company’s mission of advancing neurovascular interventions,” said Nir Nimrodi. “Rapid’s innovative portfolio is transforming patient care in stroke and aneurysm treatment, and I look forward to collaborating with the team to support its next stage of growth.”

With a career spanning executive roles at companies including Accellix, Intrexon, Life Technologies, and Proneuron Biotechnologies, Nimrodi has consistently driven innovation and scale across diverse healthcare sectors. He currently serves as an Operating Partner at ARCHIMED, a leading healthcare-focused investment firm, and sits on multiple boards in the biotech and life science fields.

“We are thrilled to welcome Nir to the Rapid Medical Board,” said Shimon Eckhouse, Ph.D., Chairperson of the Board. “His proven ability to guide healthcare companies through expansion and value creation will be invaluable as we accelerate the adoption of our pioneering neurovascular technologies worldwide.”

About Rapid Medical

Rapid Medical expands what’s possible in neurovascular treatment by pioneering advanced interventional devices that treat ischemic and hemorrhagic stroke. Utilizing proprietary manufacturing techniques, Rapid Medical’s products are remotely adjustable and fully visible. This enables physicians to respond in real-time to the anatomy and tailor the approach to every patient for better procedural outcomes. TIGERTRIEVER™ 13, 17, and 21, COMANECI™, COLUMBUS™/ DRIVEWIRE 14, and DRIVEWIRE 24 are CE marked and FDA cleared. TIGERTRIEVER XL & 25 are also CE marked. More information is available at www.rapid-medical.com.

Contacts

Ronen Eckhouse
+972-72-2503331
ronen@rapid-medical.com

Rapid Medical


Release Summary
Rapid Medical adds Nir Nimrodi to Board, fueling global expansion and breakthroughs in neuro intervention and stroke treatment..

Contacts

Ronen Eckhouse
+972-72-2503331
ronen@rapid-medical.com

Social Media Profiles
More News From Rapid Medical

Rapid Medical™ Surpasses 1,000 Cases With DRIVEWIRE™ 24 in North America and Expands Into Europe With MDR Approval

SOUTHLAKE, Texas & MARSEILLE, France--(BUSINESS WIRE)--Clinical success and MDR approval position DRIVEWIRE™ 24 as a next-generation access technology set to reshape neurovascular practice....

Rapid Medical™ Announces Enrollment in the First-Ever Study on the Cognitive Benefits of Thrombectomy for Ischemic Stroke Patients-Enabled by Advancements in Endovascular Devices

SOUTHLAKE, Texas--(BUSINESS WIRE)--Rapid Medical™ enrolls in the first study of the cognitive benefits of thrombectomy for ischemic stroke-enabled by TIGERTRIEVER’s active technology...

Rapid Medical™ Reports No Safety Concerns for Medium Vessel Occlusions in the Interim Safety Analysis of the DISTALS Study with TIGERTRIEVER™13

YOKNEAM, Israel & SOUTHLAKE, Texas & MARSEILLE, France--(BUSINESS WIRE)--Interim safety analysis of Rapid Medical's TIGERTRIEVER 13 device in the DISTALS study for medium vessel strokes concludes no safety concerns....
Back to Newsroom